Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.8 USD | +1.89% | +2.27% | -1.37% |
03-13 | Top Premarket Decliners | MT |
03-12 | JPMorgan Adjusts Price Target on iTeos Therapeutics to $27 From $29, Maintains Overweight Rating | MT |
Sales 2024 * | 3.15M 4.3M | Sales 2025 * | 8.12M 11.09M | Capitalization | 388M 530M |
---|---|---|---|---|---|
Net income 2024 * | -164M -224M | Net income 2025 * | -238M -325M | EV / Sales 2024 * | 123 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 47.8 x |
P/E ratio 2024 * |
-2.42
x | P/E ratio 2025 * |
-1.75
x | Employees | 157 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.8% |
Latest transcript on iTeos Therapeutics, Inc.
1 day | +1.89% | ||
1 week | +2.27% | ||
Current month | -20.82% | ||
1 month | -18.00% | ||
3 months | +4.35% | ||
6 months | +21.35% | ||
Current year | -1.37% |
Managers | Title | Age | Since |
---|---|---|---|
Michel Detheux
FOU | Founder | 57 | 12-03-31 |
Matthew Gall
DFI | Director of Finance/CFO | 47 | 20-05-31 |
Yvonne McGrath
CTO | Chief Tech/Sci/R&D Officer | 50 | 20-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ann Rhoads
BRD | Director/Board Member | 58 | 20-05-31 |
David Hallal
CHM | Chairman | 57 | 18-05-31 |
Director/Board Member | 52 | 18-05-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.13% | 29 M€ | -4.33% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 10.8 | +1.89% | 140,901 |
24-04-25 | 10.6 | +0.28% | 171,996 |
24-04-24 | 10.57 | -3.82% | 148,466 |
24-04-23 | 10.99 | +1.85% | 300,673 |
24-04-22 | 10.79 | +2.18% | 182,392 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.37% | 388M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ITOS Stock